Stride secures £4.6m in seed funding to expand its preventive health membership internationally.
The capital will support international growth and two technical projects involving multiomic age assessment and an artificial intelligence health copilot.
Stride provides a diagnostics-based preventive health membership, utilising DNA, blood, and gut testing alongside personalised insights.
Preventive health membership provider Stride has raised £4.6m in a seed round. The company will direct the proceeds towards international expansion alongside two specific research initiatives, including a multiomic approach to biological age assessment and an artificial intelligence health assistant.
Backers in the round include Arāya Ventures, Better Ventures, Morgan Stanley Inclusive & Sustainable Ventures, Innovate UK, the a16z Scout Fund, and various angel investors. Founded by Olympic medalist Andrew Steele, the firm delivers diagnostics using DNA, blood, and gut samples to provide users with actionable health insights.
From the founder
"For most of my life, I’ve been obsessed with understanding what makes people perform at their best. Elite athletes have long understood the value of testing, tracking and continually adapting. But that approach shouldn’t be reserved for people competing at the highest level."
Andrew Steele
Founder at Stride
Investor perspective
"Stride sits at the intersection of some of the most important shifts in healthcare: prevention, personalisation and the consumerisation of health. We believe the opportunity to help people understand and act on their health data earlier is enormous and look forward to being on the journey with Andrew and the team."
Rupa Popat
Founder and Managing Partner, Arāya Ventures
Use of funds
- 01Expand into international markets
- 02Fund research and development
Investors
Rupa Popat
Arāya Ventures
Better Ventures
Morgan Stanley Inclusive & Sustainable Ventures
Innovate UK
a16z Scout Fund